Customertimes annonce le lancement de DFG152 sur Salesforce AppExchange, la première place de marché mondiale du cloud d’entreprise 

Les clients Customertimes peuvent désormais bénéficier d’une puissante solution cloud de conformité juridique 

NEW-YORK, 5 janvier 2022 /PRNewswire/ — Customertimes a annoncé aujourd’hui le lancement de DFG152 sur Salesforce AppExchange, pour aider les entreprises à se conformer aux lois sur la protection des données au niveau des États et des pays. Solution Lightning Ready entièrement intégrée à Salesforce et à l’API REST, DFG152 élimine toute conjecture des processus de dépersonnalisation de données et de localisation.

Construit sur la plate-forme Salesforce, l’outil CT Vision de Customertimes est actuellement disponible sur AppExchange à l’adresse suivante : https://appexchange.salesforce.com/appxListingDetail?listingId=a0N3u00000OO32sEAD.

DFG152

DFG152 permet de se mettre en conformité avec la loi FZ-152 portant sur la protection des données personnelles. Entièrement intégré à l’application CT Mobile, il prend en charge toutes les solutions cloud basées sur la plateforme Salesforce et fonctionne sans modifier la logique métier Salesforce existante. DFG152 utilise un proxy inverse pour localiser ou dépersonnaliser des données à partir d’objets standards et personnalisés pour toute instance ou page de destination Salesforce, et il ne nécessite aucun matériel ni logiciel supplémentaire.

Commentaires sur l’actualité

  • « La conformité en matière de résidence des données personnelles continue d’être une préoccupation importante pour nos clients », a déclaré Alex Patsko, PDG de CT Software. « Après des années à fournir des solutions de mise en conformité en matière de données personnelles à des clients professionnels leaders du marché, nous sommes ravis de nous adresser désormais à une communauté AppExchange plus large afin que tous les clients Salesforce à travers le monde puissent mettre leur CRM en conformité avec les lois nationales et locales. »
  • « DFG152 de Customertimes est un ajout précieux à AppExchange, car il permet de se mettre en conformité avec les lois sur la protection des données personnelles sur les marchés d’Europe de l’Est, » a déclaré Woodson Martin, directeur général de Salesforce AppExchange. « AppExchange est en constante évolution pour permettre à ses partenaires de créer des solutions de pointe et ainsi stimuler la réussite des clients. »

À propos de Salesforce AppExchange

Salesforce AppExchange, la première place de marché mondiale du cloud d’entreprise, permet aux entreprises de vendre, entretenir, commercialiser et se développer de façon totalement innovante.  Avec plus de 6 000 solutions, 9 millions d’installations clients et 117 000 évaluations par des pairs, il s’agit de la source la plus complète de technologies cloud, mobiles, sociales, IdO, analytiques et d’intelligence artificielle pour les entreprises.

Ressources supplémentaires

Salesforce, AppExchange et autres sont des marques commerciales de salesforce.com, inc.

À propos de Customertimes

Customertimes Corp. est une société internationale de conseil et de génie logiciel qui se consacre à rendre les meilleures technologies informatiques accessibles aux clients. Avec plus de 4 000 projets achevés et plus de 1 600 experts hautement qualifiés, ses solutions sont conçues pour aider les clients à réaliser une véritable transformation commerciale et à maximiser leurs investissements technologiques. Précurseur en matière de services-conseils et de mise en œuvre de solutions Salesforce en Europe de l’Est et récompensée pour ses développements de produits, Customertimes Corp. est actuellement basée à New York, avec des antennes régionales à Londres, à Paris, à Toronto, à Kiev, à Minsk, à Riga et à Moscou. Pour en savoir plus, consultez le site www.customertimes.com.

Contact pour les médias :
Meriel Sikora
Customertimes
212-520-0059
meriel.sikora@customertimes.com

Conagen Successfully Develops Antioxidant Kaempferol by Precision Fermentation

Bedford, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Conagen, the Massachusetts-based biotechnology innovator, announced the successful development of antioxidant kaempferol produced by state-of-the-art, proprietary, precision fermentation. As a biotechnology company specializing in developing commercially valuable molecules for its partners and clients, Conagen’s kaempferol enables brands in nutrition, beauty, and personal care products to adopt a more natural position by formulating with clean and sustainable kaempferol.Recognized as one of nature’s most potent antioxidants, kaempferol is a flavonoid with health-promoting properties found in tea, fruits, and vegetables, especially rich in green leafy vegetables such as spinach and kale.

Rising consumer awareness towards chronic diseases such as cancer and diabetes drives the kaempferol market demand. The global kaempferol market may exceed $6.5 billion by 2025, according to a recent research report by Global Market Insights, Inc.

“We’re bringing to market a pure and natural kaempferol at affordable prices that were not possible or available until now,” said Casey Lippmeier, Ph.D. vice president of innovation at Conagen. “Conagen’s scalable, precision fermentation for producing flavonoids like kaempferol is more efficient and sustainable than what can be achieved with the chemically-synthesized or botanically-sourced molecule.”

Flavonoids are polyphenolic compounds commonly found in plants and are a significant part of the human diet. They are biosynthesized by plants and fungi as secondary metabolites and comprise a diverse group of phytonutrients.

Plants protect themselves and their fruits against biological intruders such as fungi and bacteria by using phenolic phytochemicals, including flavonoids. Accordingly, kaempferol provides powerful anti-microbial, anti-inflammatory, and immune system benefits to humans.

Dietary kaempferol in multiple studies has demonstrated a wide range of promising beneficial activities, primarily as an anti-inflammatory and antioxidant, for reducing the risk of chronic diseases, especially cancer.

Prolonged oxidative stress leads to premature aging and can trigger many degenerative diseases and cancer. Kaempferol’s powerful antioxidant property can help the body’s defense against free radicals that promote cancer development.

Conagen derived kaempferol from its molecular platform for flavonoid antioxidants, including the previously announced molecules: DHQ, also known as Taxifolin, p-coumaric acid, hydroxytyrosol, and rosmarinic acid. The development of natural kaempferol is good news for Conagen’s commercialization partner, Blue California, as kaempferol will expand its offerings of specialty ingredient solutions.

“This launch further demonstrates our talent for delivering innovative compounds which are ideal for dietary supplements and ‘clean-label’ ingredients for functional foods, beverages, and cosmetics,” said Lippmeier. “Our vision for promoting health and wellness is to continuously leverage our precision fermentation capabilities for high-quality phenolic and flavonoid phytonutrients, thus confirming our position as a leader in the development of strains and processes for making clean-label ingredients and nutraceuticals.”

Blue California has a long-standing partnership with biotechnology innovator Conagen. Conagen focuses on developing sustainable, nature-based ingredients that improve existing options in the market or represent completely novel ingredient solutions.

About Conagen

Conagen is a product-focused, synthetic biology R&D company with large-scale contract manufacturing capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

About Blue California

Blue California is a vertically integrated technology company providing innovative ingredient solutions to global partners. With more than 20 years of innovation success, our ingredients are used in commercial products and applications in nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. www.bluecal-ingredients.com

Attachment

Ana Arakelian, Head of Public Relations and Communications
Conagen
+1.781.271.1588
ana.arakelian@conagen.com

Harris acquires i2 product portfolio from IBM

OTTAWA, Ontario and CAMBRIDGE, United Kingdom, Jan. 04, 2022 (GLOBE NEWSWIRE) — Harris, a global vertical market software provider, has acquired the i2 intelligence analysis product portfolio of IBM, including the i2 Analyst’s Notebook, i2 Enterprise Insight Analysis (EIA) and i2 iBase platforms. The acquisition positions Harris to further deliver mission-critical applications for national defense, state & local law enforcement, maritime security as well as evidence management.

i2’s advanced analytics and intelligence analysis tools, such as the industry leading i2 Analyst’s Notebook, help analysts transform data into decisions in near-real-time, uncover hidden connections with visual displays, and turn overwhelming and disparate data—regardless of the source—into actionable intelligence.

The i2 product portfolio, i2 executives and their global teams will form a new Harris business unit, i2 Group, which will operate independently and autonomously. Jean Soucy, Harris Group President stated: “The acquisition of i2 is important to Harris because not only is it a proven business with an excellent international team of experts, but it also provides Harris with a feature-rich intelligence platform widely deployed by an influential customer base”, adding, “We look forward to working with our partners and customers to expand i2’s capabilities in this highly innovative space.”

“Resilience and collaboration have never been more critical for organizations as they confront the increasing complexity of intelligence analysis. We’re committed to addressing those needs by offering the most complete end-to-end intelligence analysis portfolio on the market” said Jamie Caffrey, Program Director at i2 Group. “The convergence of data and processes is transforming the industry. By integrating i2 into their existing networks, customers will be able to better leverage their data and will be empowered to unlock valuable insights that can translate into business success.”

As part of publicly traded Constellation Software Inc. (TSX: CSU), Harris’ financial strength, software industry expertise, and public safety focus were important factors in finding a forever home to execute i2 Group’s long-term growth strategies.

Visit www.i2group.com to learn more about i2 solutions.

For further information contact:

Jean Soucy
Group President
Phone: +1 581-205-9821
Email: JSoucy@harriscomputer.com

Steve Hammond
Portfolio Leader
Phone: +44 787-486-2811
Email: SHammond@harriscomputer.com

About N. Harris Computer Corporation (Harris)

Harris acquires vertical market software businesses, manages them well, and builds them for the future. Through acquisitions, Harris has grown extensively from its roots in the utilities, local government, education, and healthcare verticals to operate over 170 businesses globally across more than 20 industries. We are a part of Constellation Software Inc. (TSX: CSU), one of the world’s most active acquirers of VMS businesses.

About Constellation Software Inc.
Constellation Software acquires, manages and builds vertical market software businesses.

Expereo Appoints Ben Elms as Chief Revenue Officer

New addition strengthens executive management team of Amsterdam based global network company

AMSTERDAM, The Netherlands, Jan. 04, 2022 (GLOBE NEWSWIRE) — Expereo, the world’s leading provider of Global Internet, Cloud Access Optimization, SASE, and SD-WAN services, has today announced the appointment of Ben Elms as Chief Revenue Officer. Elms’ s overarching brief is to lead the Sales and go-to-market transformation across all channels and drive the expansion and adoption of Expereo’s services globally.

Elms brings more than 20 years of operational expertise and leadership in the telecommunications industry. Most recently, he served as the Group Director (CEO) at Vodafone Global Enterprise, a division of Vodafone Group Plc, a leading international wireless and wireline operator. Whilst there, he was responsible for leading global team managing relationships with multinational customers around the globe. During his tenure, the business outperformed the market with strong EBITDA performance and delivered significant improvements in customer and employee satisfaction whilst driving a program of operational efficiencies.

With his strong market experience, customer track record, and breadth of international expertise, he is a significant hire for the company as it continues its global growth and development.

Commenting on the appointment Irwin Fouwels, CEO at Expereo, said,

“Ben exhibits all the trademarks of a great leader, a true team player with super-strong commercial acumen and operational experience whilst demonstrating a relentless focus on the needs of the customer. Over the last few years, we see enterprises becoming even more cloud and internet-centric. Expereo has established a global leadership position in the highly attractive global cloud and software-defined networking market. I am very excited to have Ben join our company to continue our global go-to-market transformation. I am looking forward to a great partnership to take Expereo to further heights.

On joining the Expereo, Elms said:

“I am honored to be appointed as Expereo’s first Chief Revenue Officer and to lead the next phase of growth. Expereo is on an exciting journey and has developed a unique market leadership position. My immediate focus will be on serving our customers as we continue to invest and expand our market position and in building operational excellence in our go-to-market. I look forward to speaking and meeting with employees, customers, and partners and working with Irwin and the team to take the business forward in a market that has a huge opportunity.”

Elms’ appointment comes after a sustained period of acquisition and expansion for Expereo, which will continue into 2022. With Elms added to its executive management team, the business will look to further consolidate its position as a leading player in the market – delivering simplified global networks while delighting customers with the seamless delivery of complementary services from one trusted supplier

About Expereo
Expereo is the leading provider of managed network solutions, including Global internet connectivity, SD-WAN, SASE, and Cloud Access Optimization services. Expereo is the trusted partner of 30% of Fortune 500 companies and powers enterprise and government sites worldwide, helping to enhance every business’ productivity with flexible and optimal Internet performance. In Feb 2021, Vitruvian Partners international growth capital and buyout firm acquired a majority stakeholding in Expereo, alongside the leading European private equity firm Apax Partners SAS and company management.

LinkedIn | Twitter |

MEDIA CONTACT:
Sofia Pensado
Account Director
sofia@grammatikagency.com
+447540221914

Customertimes Announces DFG152 on Salesforce AppExchange, the World’s Leading Enterprise Cloud Marketplace

Customertimes’ customers can now benefit from a powerful legal compliance cloud solution 

NEW YORK, Jan. 4, 2022  /PRNewswire/ — Customertimes today announced it has launched DFG152 on Salesforce AppExchange, helping businesses comply with data protection laws at the state and country levels. A Lightning-ready solution that is fully integrated with Salesforce and REST API, DFG152 takes the guesswork out of data depersonalization and localization.

Built on the Salesforce Platform, CT Vision from Customertimes is currently available on AppExchange at https://appexchange.salesforce.com/appxListingDetail?listingId=a0N3u00000OO32sEAD.

DFG152
DFG152 enables compliance with personal data protection law FZ-152. Fully integrated with the CT Mobile application, it supports all Salesforce platform-based cloud solutions and operates without altering existing Salesforce business logic. DFG152 uses reverse proxy to localize or depersonalize data from standard and custom objects for any Salesforce instance or landing page, and it requires no additional hardware or software.

Comments on the News

  • “Personal data residency compliance continues to be of significant concern to our clients,” says Alex Patsko, CEO of CT Software. “After years of delivering personal data compliance solutions to leading enterprise customers, we are thrilled to launch it to the broader AppExchange community so that any Salesforce customer around the world can bring their CRM in line with national and local laws.”
  • “DFG152 from Customertimes is a welcome addition to AppExchange, as it enables compliance with personal data protection laws in Eastern European markets,” said Woodson Martin, GM of Salesforce AppExchange. “AppExchange is constantly evolving to enable our partners to build cutting-edge solutions to drive customer success.”

About Salesforce AppExchange 
Salesforce AppExchange, the world’s leading enterprise cloud marketplace, empowers companies to sell, service, market and engage in entirely new ways. With more than 6,000 solutions, 9 million customer installs and 117,000 peer reviews, it is the most comprehensive source of cloud, mobile, social, IoT, analytics, and artificial intelligence technologies for businesses.

Additional Resources

Salesforce, AppExchange and others are among the trademarks of salesforce.com, inc.

About Customertimes
Customertimes Corp. is a global consulting and software firm dedicated to making the top IT technologies accessible to customers. With more than 4000 projects completed and 1600+ highly skilled experts, their solutions are engineered to help clients realize true business transformation and achieve maximum value from their technology investments. An early entrant into the Salesforce consulting and implementation space in Eastern Europe and an award-winning product development organization, Customertimes Corp. currently has headquarters in New York City, along with regional offices in London, Paris, Toronto, Kyiv, Minsk, Riga, and Moscow. For more information, visit www.customertimes.com.

Media Contact:
Meriel Sikora
Customertimes
212-520-0059
meriel.sikora@customertimes.com

US Advisers Endorse Pfizer COVID Boosters for Younger Teens

Influential government advisers are strongly urging that teens as young as 12 get COVID-19 boosters as soon as they’re eligible, a key move as the U.S. battles the omicron surge and schools struggle with how to restart classes amid the spike.

All Americans 16 and older are encouraged to get a booster, which health authorities say offers the best chance at avoiding the highly contagious omicron variant. Earlier this week, the Food and Drug Administration authorized an extra Pfizer shot for kids ages 12 to 15, as well — but that wasn’t the final hurdle.

The Centers for Disease Control and Prevention makes recommendations for vaccinations and on Wednesday, its advisers voted that a booster was safe for the younger teens and should be offered to them once enough time — five months — has passed since their last shot. And while the CDC last month opened boosters as an option for 16- and 17-year-olds, the panel said that recommendation should be strengthened to say they “should” get the extra dose.

CDC director Dr. Rochelle Walensky will weigh the panel’s advice before making a final decision soon.

Vaccines still offer strong protection against serious illness from any type of COVID-19, including the highly contagious omicron variant, especially after a booster. But omicron can slip past a layer of the vaccines’ protection to cause breakthrough infections.

Studies show a booster dose at least temporarily revs up virus-fighting antibodies to levels that offer the best chance at avoiding symptomatic infection, even from omicron.

Fending off even a mild infection is harder for vaccines to do than protecting against serious illness, so giving teens a booster for that temporary jump in protection is like playing whack-a-mole, cautioned Dr. Sarah Long of Drexel University. But she said the extra shot was worth it given how hugely contagious the omicron mutant is, and how many kids are catching it.

More important, if a child with a mild infection spreads it to a more vulnerable parent or grandparent who then dies, the impact “is absolutely crushing,” said Dr. Camille Kotton of Massachusetts General Hospital.

“Let’s whack this one down,” agreed Dr. Jamie Loehr of Cayuga Family Medicine in Ithaca, New York.

The vaccine made by Pfizer and its partner BioNTech is the only option for American children of any age. About 13.5 million children ages 12 to 17 have received two Pfizer shots, according to the CDC. Boosters were opened to the 16- and 17-year-olds last month.

The CDC’s advisers were swayed by real-world U.S. data showing that symptomatic COVID-19 cases and hospitalizations are between seven and 11 times higher in unvaccinated adolescents than vaccinated ones.

If the CDC agrees, about 5 million of the younger teens, those 12 to 15, would be eligible for a booster right away because they got their last shot at least five months ago.

New U.S. guidelines say anyone who received two Pfizer vaccinations and is eligible for a booster can get it five months after their last shot, rather than the six months previously recommended.

Children tend to suffer less serious illness from COVID-19 than adults. But child hospitalizations are rising during the omicron wave — the vast majority of them unvaccinated.

During the public comment part of Wednesday’s meeting, Dr. Julie Boom of Texas Children’s Hospital said a booster recommendation for younger teens “cannot come soon enough.”

The chief safety question for adolescents is a rare side effect called myocarditis, a type of heart inflammation seen mostly in younger men and teen boys who get either the Pfizer or Moderna vaccines. The vast majority of cases are mild — far milder than the heart inflammation COVID-19 can cause — and they seem to peak in older teens, those 16 and 17.

The FDA decided a booster dose was as safe for the younger teens as the older ones based largely on data from 6,300 12- to 15-year-olds in Israel who got a Pfizer booster five months after their second dose. Israeli officials said Wednesday that they’ve seen two cases of mild myocarditis in this age group after giving more boosters, 40,000.

Earlier this week, FDA vaccine chief Dr. Peter Marks said the side effect occurs in about 1 in 10,000 men and boys ages 16 to 30 after their second shot. But he said a third dose appears less risky, by about a third, probably because more time has passed before the booster than between the first two shots.

Source: Voice of America